« Back to news

£55 million Catapult boost for Stevenage Bioscience Catalyst

£55 million Catapult boost for Stevenage Bioscience Catalyst

blog image

The Cell Therapy Catapult, which is focused on the development of the UK’s cell therapy industry, has chosen to build its new £55 million state-of-the-art Cell Therapy manufacturing centre at Stevenage Bioscience Catalyst (SBC).

The UK Cell Therapy Manufacturing Centre, which is expected to open in 2017, will be used for manufacture of late phase clinical trial and commercial supply of advanced therapeutic medicinal products including cell and gene therapies.  

The large-scale manufacturing facility is expected to create up to 150 jobs and generate £1.2 bn of revenue by 2020 (80% via export).

Catapult centres are being established and overseen by Innovate UK as a new addition to its range of programmes to stimulate innovation and bring new products and services more quickly to commercialisation.

Iain Gray, Chief Executive of Innovate UK, said: : “This is an exciting development for the Cell Therapy Catapult and an important next step in the establishment of the UK as a global manufacturing centre for the cell therapy industry. The choice of Stevenage follows a rigorous selection process to ensure the right location for this important facility." 

“This is terrific news that we have met all the criteria for locating this facility here,” said Martino Picardo, CEO of SBC. “Our open innovation campus is a unique and thriving bioscience community with the benefit of excellent UK and international logistics. Companies coming to the Cell Therapy Catapult’s Manufacturing Centre will also be able to access our expertise, networks and scientific facilities traditionally associated with multinational pharmaceutical companies.” 

Keith Thompson, CEO of the Cell Therapy Catapult said: “This facility will complement the existing UK capability, enabling companies to operate at the scale needed for Phase III clinical trials, and we look forward to working with global scientific and medical communities to assist in their research into products that have the potential to address many unmet medical needs.”   


Share this: